Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fg12 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response

Journal of Immunology

Volumn 160, Issue 7, 1998, Pages 3487-3493

  Ning, Qin ^a   Brown, Deron ^a   Parodo, Jean ^a   Cattral, Mark ^a   Gorczynski, Reginald ^a   Cole, Edward ^a   Fung, Laisum ^a   Ding, Jin Wen ^a   Liu, Ming Feng ^a   Rotstein, Ori ^a   James Phillips, M ^a   Levy, Gary ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; INTERLEUKIN 1; RIBAVIRIN; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFECT; IMMUNE RESPONSE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; VIRUS CELL INTERACTION; VIRUS INFECTION;

ANIMALS; CORONAVIRUS INFECTIONS; CYTOKINES; FEMALE; FIBRINOGEN; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-1; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED A; MICE, INBRED BALB C; MICE, INBRED C3H; MURINE HEPATITIS VIRUS; RIBAVIRIN; RNA, MESSENGER; TH1 CELLS; TH2 CELLS; THROMBOPLASTIN; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032055507     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Sidwell, R. W., J. H. Hoffman, G. P. Khare, L. B. Allen, J. T. Witkowski, and R. K. Robins. 1972. Broad-spectrum antiviral activity of virazole: 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177:705.
2. Heagy, W., C. Crumpaker, P. A. Lopez, and R. W. Finberg. 1991. Inhibition of immune functions by antiviral drugs. J. Clin. Invest. 87:1916.
3. Jolley, W. B., B. Sharma, R. Charni, C. Ng, and R. Bullington. 1988. Long term skin allograft survival by combined therapy with suboptimal dose of cyclosporine and ribavirin. Transplant. Proc. 20:703.
4. Sidwell, R. W., J. H. Huffman, N. Campbell, and L. B. Allen. 1977. Effect of ribavirin on viral hepatitis in laboratory animals. Ann. NY Acad. Sci. 284:239.
5. Levy, G. A., J. L. Leibowitz, and T. S. Edgington. 1981. Induction of monocyte procoagulant activity by murine hepatitis virus type 3 parallels disease susceptibility in mice. J. Exp. Med. 154:1150.
6. Li, C, L. S. Fung, A. Crow, N. Myers-Mason, J. L. Leibowitz, E. Cole, and G. A. Levy. 1992. Monoclonal anti-prothrombinase (3D4.3) prevents mortality from murine hepatitis virus infection (MHV-3). J. Exp. Med. 176:689.
7. Fung, L. S., G. Neil, J. L. Leibowitz, E. Cole, S. Chung, A. Crow, and G. A. Levy. 1991. Monoclonal antibody analysis of a unique macrophage procoagulant activity induced by murine hepatitis virus strain 3 infection. J. Biol. Chem. 266:1789.
8. Pope, M., S. W. Chung, T. Mosmann, J. L. Leibowitz, R. M. Gorczynski, and G. A. Levy. 1996. Resistance of naive mice to murine hepatitis virus strain 3 (MHV-3) requires development of Th1, but not Th2 response, whereas pre-existing antibody protects against primary infection. J. Immunol. 156:3342.
9. Terry, Y. Y., R. M. Gorczynski, S., Iwasuki, D. B. Williams, and N. Hozumi. 1995. Evidence for Th2 cell-mediated suppression of antibody enzymes in transgenic, beef insulin tolerant mice. Eur. J. Immunol. 25:2522.
10. Arnstein, H. R., and R. A. Cox. 1966. Isolation of nucleic acids. Br. Med. Bull. 22:158.
11. Parr, R. L., L. Fung, J. Reneker, N. Myers-Mason, J. L. Leibowitz, and G. A. Levy. 1995. Association of mouse fibrinogen-like protein with murine hepatitis virus-induced prothrombinase activity. J. Virol. 69:5033.
12. Caput, D., B. Beutler, K. Hartog, R. Thayer, S. Brown-Shimer, and A. Cerami. 1986. Identification of a common nucleotide sequence in the 3′ untranslated region of mRNA molecules specifying inflammatory mediators. Proc. Natl. Acad. Sci. USA 83:1670.
13. Lomedico, P. T., U. Gubler, C. P. Hellmann, M. Dukovich, J. G. Giri, E. P. Yu-Chung, K. Collier, R. Smionow, A. O. Chua, and Mizel S. B. 1984. Cloning and expression of murine interleukin-1 cDNA in Escherichia coli. Nature 312:458.
14. Lee, W. J. 1993. Acute liver failure. N. Engl. J. Med. 329:1862.
15. Fried, M. W., T. L. Fong, M. G. Swain, Y. Park, M. P. Beames, S. M. Banks, J. H. Hoofnagle, and A. M. Di Bisceglie. 1994. Therapy of chronic hepatitis B with a 6-month course of ribavirin. J. Hepatol. 21:145.
16. Di Bisceglie, A. M., H. S., Conjeevaram, M. W. Fried, R. Sallie, Y. Park, C. Yurdaydin, M. Swain, D. E. Kleiner, K. Mahoney, and J. Hoofnagle. Ribavirin as therapy for chronic hepatitis C: a randomized, double-blind, placebo controlled trial. Ann. Intern. Med. 1995;123:897.
17. Di Bisceglie, A. M., M. Shindo, T. L. Fong, M. W. Fried, M. G. Swain, N. V. Gergasa, C. A. Axiotis, J. G. Waggnoger, Y. Park, and J. H. Hoofnagle. 1992. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 16: 649.
18. Cattral, M. S., M. Krajden, I. R. Wanless, M. Rezeig, R. Cameron, P. D. Greig, S. W. Chung, and G. A. Levy. 1996. A pilot study of ribavirin therapy for recurrent hepatitis C virus infection after liver transplantation. Transplantation 61:1483.
19. Levy, G. A., J. L. Leibowitz, and T. S. Edgington. 1981. Induction of monocyte procoagulant activity by murine hepatitis virus type 3 parallels disease susceptibility in mice. J. Exp. Med. 154:1150.
20. Pope, M., O. Rotstein, E. Cole, S. Sinclair, R. Parr, B. Cruz, R. Fingerote, S. Chung, R. Gorczynski, L. Fung, J. L. Leibowitz, and G. A. Levy. 1995. Pattern of disease after murine hepatitis virus strain 3 infection correlates with macrophage activation and not viral replication. J. Virol. 69:5252.
21. Pope, M., O. Rotstein, B. Cruz, R. Fingerote, S. Chung, R. Gorczynski, Y. S. Rao, and Levy, G. A. 1994. Pattern of cytokine production in fulminant murine hepatitis virus infection. Hepatology, 29:294A.
22. Levy, G. A., R. Shaw, J. L. Leibowitz, and E. Cole. 1984. The immune response to mouse hepatitis virus: genetic variation in antibody response and disease. Adv. Exp. Med. Biol. 173:345.
23. Chung, S., R. Gorczynski, B. Cruz, R. Fingerote, E. Skamene, S. Perlman, J. Leibowitz, L. Fung, M. Flowers, and G. A. Levy. 1994. A Th1 helper cell line (3E9.1) from resistant A/J mice inhibits induction of macrophage procoagulant activity in vitro and protects against MHV-3 mortality in vivo. Immunology 83: 353.
24. Sinclair, S. B., O. D. Rotstein, and G. A. Levy. 1990. Disparate induction of procoagulant activity by live and inactivated bacteria and viruses. Infect. Immun. 58:1821.
25. McCormick, J. B., J. P. Getchell, S. W. Mitchell, and D. R. Hicks. 1984. Ribavirin suppresses replication of lymphadenopathy-associated virus in culture of human adult T lymphocytes. Lancet 2:1367.
26. Vogt, M. W., K. L. Hartshorn, P. A. Furman, T. C. Chou, J. A. Fyfe, L. A. Coleman, C. Crumpacker, R. T. Schooley, and M. S. Hirsch. 1987. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 235: 1376.
27. J. M. Cavaillon. 1994. Cytokines and macrophages. Biomed. Pharmacother. 48: 445.
28. Shigemi, S., H. Tsutsumi, R. Takeuchi, K. Matsuda, S. Imai, P. L. Ogra, and S. Chiba. 1997. Enhanced cytokine production by milk macrophages following infection with respiratory syncytial virus. J. Leuk. Biol. 61:630.
29. Dindzans, V. J., P. J. Macphee, L. S. Fung, J. L. Leibowitz, and G. A. Levy. 1985. The immune response to mouse hepatitis virus: expression of monocyte procoagulant activity and plasminogen activator during infection in vivo. J. Immunol. 135:4189.
30. MacPhee, P. J., V. J. Dindzans, L. S. Fung, and G. A. Levy. 1985. Acute and chronic changes in the microcirculation of the liver in inbred strains of mice following infection with mouse hepatitis virus type 3. Hepatology 9:349.
31. Dindzans, V. J., E. Skamene, and G. A. Levy. 1986. Susceptibility/resistance to mouse hepatitis virus strain 3 and macrophage procoagulant activity are genetically linked and controlled by two non-H-2-linked genes. J. Immunol. 137:2355.
32. Abecassis, M., J. A. Falk, L. Makowka, V. J. Dindzans, R. E. Falk, and G. A. Levy. 1987. 16,16 Dimethyl prostaglandin E2 (PGE2) prevents the development of fulminant hepatitis and blocks the induction of monocyte procoagulant activity (PCA) following murine hepatitis virus strain 3 (MHV-3) infection. J. Clin. Invest. 80:881.
33. Sinclair, S. B., A. Wakefield, and G. A. Levy. 1990. Fulminant hepatitis. Semin. Immunopathol. 12:1.
34. Chung, S. W., C. Y. Li, J. L. Leibowitz, and G. A Levy. 1994. The role of procoagulant activity in fulminant viral hepatitis,. In Role of Procoagulant Activity in Health and Disease. G. A. Levy and E. H. Cole, eds. CRC Press, Boca Raton, FL, p. 111.
35. Koyama, K. L., L. R. Hall, W. G. Haser, S. Tonegawa, and H. Saito. 1987. Structure of a cytotoxic T lymphocyte-specific gene shows a strong homology to fibrinogen beta and gamma chains. Proc. Natl. Acad. Sci. USA 84:1609.
36. Laskin, D. L. 1990. Nonparenchymal cells and hepatotoxicity. Semin. Liver Dis. 10:293.
37. Winwood, P. J., and M. P. Arthur. 1993. Kupffer cells: their activation and role in animal models of liver injury and human liver disease. Semin. Liver Dis. 13:50.
38. Chisari, F V. 1995. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 13:29.
39. Bevilacqua, M., J. Pober, G. Majeau, R. Cotran, and M. Gimbrone. 1984. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J. Exp. Med. 160:618.
40. Nawroth, P. P., and D. M. Stern. 1986. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J. Exp. Med. 163:740.
41. Mosmann T. R., and R. L. Coffman. 1989. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145.
42. Heinzel, F. P., M. D. Sadick, B. J. Holadray, R. L. Coffman, and R. M. Locksley. 1989. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis: evidence for expansion of distinct helper T cell subsets. J. Exp. Med. 169:59.
43. Scott, P. 1991. IFN-γ modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. J. Immunol. 147:3149.
44. Belosevic, M., D. S. Finbloom, P. H. Van der Meide, M. V. Slayter, and C. Nacy. 1989. Administration of monoclonal anti-IFN-gamma antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major. J. Immunol. 143:266.
45. Swain, S. L., A. D. Weinberg, M. English, and G. Huston. 1990. IL-4 directs the development of Th2-like helper effectors. J. Immunol. 145:3796.
46. Chatelain. R., K. Varkila, and R. L. Coffman. 1992. IL-4 induces a Th2 response in Leishmania major-infected mice. J. Immunol. 148:1182.
47. Romani, L., A. Mencacci, U. Grohmann, P. Mosci, P. Puccetti, and F. Bisstoni. 1992. Neutralizing antibody to interleukin 4 induces systemic protection and T helper type 1-associated immunity in murine candidiasis. J. Exp. Med. 176:19.
48. Modlin, R. L., and T. B. Nutman. 1993. Type 2 cytokines and negative immune regulation in human infections. Curr. Opin. Immunol. 5:511.
49. J. F. Schlaak, T. Baecker, H. F. Lohr, and K.-H. Meyer zum Buschenfelde. 1996. Chronic hepatitis C: IL-12 enhances HCV-antigen induced cytokine production of PBMC in a subgroup of patients. Hepatology 24:265A.
50. M. Lechmann, B. Langhans, S. Bar, R. Woitas, L. Leifeld, H. G. Ihlenfeldt, G. Jung, W. Effenberger, T. Sauerbruch, and U. Spengler. 1996. Deficient secretion of TH1 cytokines in patients with chronic hepatitis C. Hepatology 24:266A.
51. R. P. Woitas, M. Lechmann, B. Langhans, S. Bar, H. G. Ihlenfeldt, G. Jung, T. Sauerbruch, and U. Spengler. 1996. Cytokine response to hepatitis C virus core peptides in patients with chronic hepatitis C infection and healthy anti-HCV seropositives. Hepatology 24:266A.